Clinical Trials

50 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07024615 2026-03-13

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1 Recruiting

25 enrolled

Phase EARLY_PHASE1 Active not recruiting

Pancreatic Ductal Adenocarcinoma

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

2 enrolled

Phase 3 Not yet recruiting

Colonic Neoplasms

NCT07463573 2026-03-11

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

466 enrolled

Esophageal Squamous Cell Carcinoma

NCT05239741 2026-03-10

MK-3475-C66

100 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

20 enrolled

Gastroesophageal Adenocarcinoma

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

572 enrolled

Stomach Neoplasms

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

46 enrolled 15 charts

Phase 2 Active not recruiting

Pancreatic Neoplasms

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

123 enrolled 15 charts

Pancreatic Neoplasms

NCT04230187 2026-03-05

TRIBE-C

528 enrolled

Colorectal Neoplasms

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

382 enrolled

Phase 1 Active not recruiting

Adenocarcinoma Of Esophagus

NCT05722327 2026-03-04

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

24 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT05846867 2026-03-04

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

170 enrolled

Colorectal Neoplasms

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

560 enrolled

Phase 3 Active not recruiting

Colorectal Adenocarcinoma

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Rectal Neoplasms

NCT05319730 2026-03-02

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05863195 2026-03-02

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

408 enrolled

Phase 2 Enrolling by invitation

Colorectal Neoplasms

NCT07441369 2026-03-02

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

16 enrolled

Phase 3 Active not recruiting

Liver Metastases From Colorectal Cancer (mCRC)

NCT06356311 2026-02-27

TroFuse-015

450 enrolled

Adenocarcinoma Of Esophagus

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1/2 Recruiting

81 enrolled

Fibrolamellar hepatocellular carcinoma

NCT04469556 2026-02-20

PASS-01

150 enrolled

Pancreatic Cancer Metastatic

NCT06998940 2026-02-20

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Phase 1 Completed

13 enrolled

Pancreatic Neoplasms

NCT05669339 2026-02-18

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

12 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT05466799 2026-02-13

TRIPP-FFX

88 enrolled

Locally Advanced Pancreatic Cancer

NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

224 enrolled

Biliary Tract Neoplasms, Stomach Neoplasms

NCT06501989 2026-02-11

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Colorectal Neoplasms

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

240 enrolled 14 charts

Phase 3 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Pancreatic Neoplasms

NCT05412082 2026-02-06

SMART TNT

Phase 1 Recruiting

25 enrolled

Phase 1 Active not recruiting

Locally Advanced Rectal Cancer

NCT05838768 2026-02-06

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

327 enrolled

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT07391566 2026-02-06

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

99 enrolled

Colorectal Neoplasms

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

42 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00989469 2026-02-05

NEXIRI

Phase 1/2 Completed

64 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

34 enrolled

Colorectal Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Colonic Neoplasms

NCT06958328 2026-02-02

LAP100

356 enrolled

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

GastrointestinalGenitourinary

Pancreatic Neoplasms

NCT03798626 2026-01-27

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

167 enrolled

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Phase 1 Completed

21 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT07265674 2026-01-23

Beacon-BTC

480 enrolled

Phase 1 Not yet recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

Phase 1/2 Not yet recruiting

Colorectal Neoplasms

NCT07364422 2026-01-23

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

49 enrolled

Stomach Neoplasms

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

550 enrolled